Loading
Lamassu Biotech is testing a tablet that switches back on p53, a protein that normally stops cancer growth, in tumours where p53 itself is still intact.
Lamassu Biotech is a private clinical-stage company that announced corporate offices in Cleveland in May 2024 and develops small molecules for oncology and metabolic indications, including a treatment for acute pancreatitis and a veterinary arm, Lamassu Pets. SA53 (SA53-OS) is an oral MDM2 inhibitor designed to reactivate wild-type p53, in a first-in-human phase 1/2a study (LB-SA53-101) in locally advanced or metastatic solid tumours (NCT06578624); initial safety and pharmacokinetic data were presented at ESMO 2026. Its first registered cancer trial, NCT06578624, was posted on ClinicalTrials.gov in August 2024.
Shares MDM2 inhibitors, MDM2.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/